Abstract:This work developed a biohybrid bacterial system through genetic engineering and biomaterial hybridization in which CDH17 nanobodies are engineered onto the bacteria for tumor targeting and a photothermal material croconium (CR) dye is conjugated on bacteria for PTT induction. When combined with checkpoint blockade CD47 nanobody, the biohybrid bacteria successfully eradicated the tumors through STING activation, and considerably extended survival of the mice. Bacteria can be utilized for cancer therapy owing to their preferential colonization at tumor sites. However, unmodified non‐pathogenic bacteria carry potential risks due to their non‐specific targeting effects, and their anti‐tumor activity is limited when used as monotherapy. In this study, a biohybrid‐engineered bacterial system comprising non‐pathogenic MG1655 bacteria modified with CDH17 nanobodies on their surface and conjugated with photosensitizer croconium (CR) molecules is developed. The resultant biohybrid bacteria can efficiently home to CDH17‐positive tumors, including gastric, pancreatic, and colorectal cancers, and significantly suppress tumor growth upon irradiation. More importantly, biohybrid bacteria‐mediated photothermal therapy (PTT) induced abundant macrophage infiltration in a syngeneic murine colorectal model. Further, that the STING pathway is activated in tumor macrophages by the released bacterial nucleic acid after PTT is revealed, leading to the production of type I interferons. The addition of CD47 nanobody but not PD‐1 antibody to the PTT regimen can eradicate the tumors and extend survival. This results indicate that bacteria endowed with tumor‐specific selectivity and coupled with photothermal payloads can serve as an innovative strategy for low‐immunogenicity cancers. This strategy can potentially reprogram the tumor microenvironment by inducing macrophage infiltration and enhancing the efficacy of immunotherapy targeting macrophages.

Engineering Proteus Mirabilis Improves Antitumor Efficacy Via Enhancing Cytotoxic T Cell Responses

Proteus Mirabilis Inhibits Cancer Growth and Pulmonary Metastasis in a Mouse Breast Cancer Model

Programmable Bacteria with Dynamic Virulence Modulation System for Precision Antitumor Immunity

Tweak to Treat: Reprograming Bacteria for Cancer Treatment

Engineering Bacteria and Their Derivatives for Cancer Immunotherapy

Probiotic Engineering and Targeted Sonoimmuno-Therapy Augmented by STING Agonist.

Engineering bacteria for cancer immunotherapy

In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity

Harnessing Bacterial Agents to Modulate the Tumor Microenvironment and Enhance Cancer Immunotherapy

Path to bacteriotherapy: From bacterial engineering to therapeutic perspectives

Nanobody‐Engineered Biohybrid Bacteria Targeting Gastrointestinal Cancers Induce Robust STING‐Mediated Anti‐Tumor Immunity

Self-adjusting Engineered Probiotic for Targeted Tumor Colonization and Local Therapeutics Delivery

Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field

Progress of engineered bacteria for tumor therapy

Synergistic Brilliance: Engineered Bacteria and Nanomedicine Unite in Cancer Therapy

Engineered Bacteria: Strategies and Applications in Cancer Immunotherapy

Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors

Genetically engineered probiotics for an optical imaging-guided tumor photothermal therapy/immunotherapy

Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin

Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy

Remolding the Tumor Microenvironment by Bacteria Augments Adoptive T Cell Therapy in Advanced-Stage Solid Tumors